Manténgase sano!

For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.

In the study, published Saturday in the New England Journal of Medicine, researchers reported that the drug helped people with typ...

The U.S. Food and Drug Administration on Tuesday approved the country's first continuous glucose monitor for type 2 diabetes.

The new Dexcom Stelo Glucose Biosensor System, which will be available by summer, is intended for people 18 and older who have type 2 diabetes but do not take insulin, according to the agency.

Also known as CGMs, these monitors consist of tiny sensors that pr...

The U.S. Food and Drug Administration is investigating reports of additional dangers linked to several wildly popular weight-loss drugs.

In a quarterly report...

Managing diabetes will be a less expensive proposition for more Americans in 2024.

Sanofi has officially joined Novo Nordisk and Eli Lilly in lowering the cost of insulin to $35 a month for many patients. The three drugmakers are also drastically lowering the list prices for their insulin pr...

New research suggests some newer diabetes treatments may not be as beneficial for Black patients, after earlier drug trials included small numbers of non-white people.

Whether the medications -- called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-Ras) -- actually have less benefit for Black patients or whether the small sample s...

Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're "fraudulently claiming"that their compounded products are the same as its medication.

This time, it's Eli Lilly suing certain medical spas, wellness centers and compounding pharmacies over its medication Mounjaro.

Mounjaro contains the active ingredient tirzepatide and is ...

As demand for the wildly popular weight-loss drug Wegovy continues to climb, drug maker Novo Nordisk said Thursday that it will continue restrictions on starter doses of the medication into 2024.

The new plan extends by months existing restrictions and means patients who are not already taking the medication will have to wait to start.

"We are going to continue to supply the market,...

The diabetes drug metformin might also benefit older patients after an injury or illness, a small study suggests.

Researchers found that metformin -- a drug that has been around for more than a half-century to regulate blood sugar -- may have a different ability: It can target senescent cells that affect muscle function. These "zombie-like" cells release chemicals linked with inflammation...

People with type 2 diabetes could soon have access to convenient once-a-week insulin shots that could replace the daily injections now required.

A once-weekly insulin formulation called icodec performed just as well as daily doses of the insulin degludec, phase 3 clinical trial results show.

Icodec now awaits approval by the U.S. Food and Drug Administration based on these results, ...

You have been diagnosed with type 2 diabetes. What are your medication options?

That depends on what type of diabetes you have and what risk factors you carry.

In type 2 diabetes, the body becomes resistant to the insulin and the pancreas has to make more. Insulin resistance can be caused by obesity, lack of exercise, medication, stress or hereditary factors. Initially, the pancreas...

The trendy weight-loss drug Ozempic could be dangerous for a patient undergoing anesthesia for an operation, according to a new warning from the American Society of Anesthesiologists.

Semaglutide (Ozempic, Wegovy) and other drugs of their class known as GLP-1 receptor agonists cause digestion to slow down, which decreases hunger and reduces how much people eat.

That food left in the...

After drugmaker Novo Nordisk tweaked its diabetes drug Ozempic into Wegovy -- a formulation expressly designed to help users shed pounds -- sales of both drugs skyrocketed.

Other pharmaceutical giants took notice, and over the past weekend the results of multiple clinical trials from would-be competitors were unveiled at this year's annual meeting of the American Diabetes Association (ADA...

The maker of three popular drugs that treat weight loss and diabetes said Tuesday that it has begun legal proceedings against businesses that are selling compounded versions of its products that are not approved by the U.S. Food and Drug Administration.

In a sta...

A safe, generic diabetes pill can help people avoid long COVID, a new clinical trial shows.

Metformin cut the risk of long COVID by about 40% for patients who received a two-week course of the drug while battling their infection, the researchers reported.

The results were even more dramatic if COVID-19 patients began taking metformin soon after infection. Starting on the drug w...

There are many medications for type 2 diabetes, but one class may stand out for protecting the heart, a new study suggests.

The study, of thousands of U.S. veterans with diabetes, found that those who added drugs called GLP-1 receptor agonists to their usual regimen were somewhat less likely to suffer a first-time heart attack or stroke in coming years.

That was in comparison to vet...

More Americans will soon be paying less for their insulin.

Eli Lilly, one of the three insulin manufacturers, plans to cut its list prices of the drug by 70% and cap out-of-pocket costs at $35 a month.

"While the current health care system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone, and that needs to change," E...

Most Americans with type 2 diabetes are candidates for newer, pricey medications, but few are getting them, a new government study shows.

Researchers found that of U.S. adults with the blood sugar disease, over 80% could stand to benefit from the medications, based on recommendations from the American Diabetes Association (ADA). But only 10% of those people were actually taking the drugs ...

While people with type 1 diabetes can see some benefit from newer medications prescribed off-label, there is also risk, and these patients should be monitored closely, according to a new study.

Type 1 diabetes is universally treated with insulin injections, but only about one-fifth of patients achieve blood sugar control with it,